StemRIM Inc. announced that it has entered into a contract for the implementation of a Phase 2 investigator-initiated clinical trial targeting ischemic cardiomyopathy using Redasemtide, in collaboration with Osaka University Hospital and Shionogi & Co. Ltd. This clinical trial will be conducted as an investigator-in initiated clinical trial mainly at Osaka University Hospital and is planned to start in the first half of 2024, with the primary objective of evaluating the efficacy and safety of Redasemtide in patients with ischemic cardiomyopath. Under the terms of the agreement, StemRIM and Shionogi will support the implementation of the clinical trial by providing the investigational drug, information necessary for the submission of the notification of clinical trial, and support for the preparation of various materials related to the clinical trial.

Redasemtide is a candidate for the development of "Regeneration-Inducing MedicineTM", which regenerates tissue damaged by injury or disease through the administration of medication without the use of living cells. Ischemic cardiomyopathy will be the fifth indication for which Redasemtide is being tested in Phase 2 clinical trials, following dystrophic epidermolysis bullosa, acute ischemic stroke, osteoarthritis of the knee, and chronic liver disease.